Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00519831
Status:
TERMINATED
Last Update Posted:
2017-06-09
First Post:
2007-08-21
Brief Title:
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
UNC Lineberger Comprehensive Cancer Center
Organization Data
Organization:
UNC Lineberger Comprehensive Cancer Center
Class:
OTHER
Study ID:
UNC LCCC 0503
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |